Loading...

SOHO 2026 Annual Meeting

This website and third-party tools we use rely on cookies for the best user experience. By selecting "I agree", you agree to cookie usage as described in our Privacy Policy.

1,267 posters, 47 videos, 13 topics, 4 sessions, 853 authors

ePostersLive by SciGen Technologies S.A. All rights reserved.

SOHO 2026 Annual Meeting

September 9 - 12, 2026 | George R. Brown Convention Center, Houston, Texas

Home Posters by Code Posters by Title Authors Topics Sessions Videos Previous meetings

Posters by Session

Select Session

Thumbnail for Risk Stratification Using Machine Learning Phenotypes in Acute Myeloblastic Leukemia Patients With Septic Shock

AML - 260

Risk Stratification Using Machine Learning Phenotypes in Acute Myeloblastic Leukemia Patients With Septic Shock

Aishwarya Ramesh

Poster Presenter: Aishwarya Ramesh

Thumbnail for Venetoclax-Based Therapy Is Associated With Improved Survival in Acute Myeloid Leukemia: A Large Real-World Study

AML - 283

Venetoclax-Based Therapy Is Associated With Improved Survival in Acute Myeloid Leukemia: A Large Real-World Study

Fareeha Abdulwali

Poster Presenter: Fareeha Abdulwali

Thumbnail for Integrating Molecular Profiling To Predict Immunophenotypic MRD Clearance in Acute Myeloid Leukemia

Previous 1...33 34 35 36 37 38 39...141 Next

Copyright © 2015-2026, ePostersLive® SciGen is a registered trademark of SciGen Technologies S.A. Patent pending.

AML - 289

Integrating Molecular Profiling To Predict Immunophenotypic MRD Clearance in Acute Myeloid Leukemia

Ekaterina Motyko

Poster Presenter: Ekaterina Motyko

Thumbnail for Weekly Hypomethylating Agent and Venetoclax Combination Therapy in Myeloid Neoplasms: A Real-World Single-Center Experience in an Older, High-Comorbidity Population

AML - 292

Weekly Hypomethylating Agent and Venetoclax Combination Therapy in Myeloid Neoplasms: A Real-World Single-Center Experience in an Older, High-Comorbidity Population

Mahmood Aldapt

Poster Presenter: Mahmood Aldapt

Thumbnail for ADAM17-Driven NKG2D Ligand Shedding Defines a Leukemia-Intrinsic Immune Evasion Program That Predicts Venetoclax Resistance and Reveals MEK and PI3K As Therapeutic Vulnerabilities in AML

AML - 296

ADAM17-Driven NKG2D Ligand Shedding Defines a Leukemia-Intrinsic Immune Evasion Program That Predicts Venetoclax Resistance and Reveals MEK and PI3K As Therapeutic Vulnerabilities in AML

Abdelrahman Masheh

Poster Presenter: Abdelrahman Masheh

Thumbnail for Oral Azacitidine Maintenance vs Observation in Acute Myeloid Leukemia in First Remission: A Systematic Review and Pooled Analysis of Randomized Evidence

AML - 301

Oral Azacitidine Maintenance vs Observation in Acute Myeloid Leukemia in First Remission: A Systematic Review and Pooled Analysis of Randomized Evidence

Elias Tayar

Poster Presenter: Elias Tayar

Thumbnail for Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy

AML - 327

Steroid-Associated Toxicities and Survival Outcomes in Acute Promyelocytic Leukemia Treated With ATO/ATRA With or Without Chemotherapy

Gautam Pantwalawalkar

Poster Presenter: Gautam Pantwalawalkar

Thumbnail for Widening Racial and Urban-Rural Disparities in AML Mortality in the Targeted Therapy Era: A Population-Level Analysis of US Mortality Trends, 2018-2024

AML - 336

Widening Racial and Urban-Rural Disparities in AML Mortality in the Targeted Therapy Era: A Population-Level Analysis of US Mortality Trends, 2018-2024

Tapan Giri

Poster Presenter: Tapan Giri

Thumbnail for MYELOVAC: A Phase 1 Trial of a Personalized Peptide-Based Neoantigen Vaccination Platform in Combination With Hypomethylating Agent-Based Therapy for Patients With Acute Myeloid Leukemia in First Complete Remission Ineligible for Intensive Chemotherapy and Allogeneic Stem Cell Transplantation

AML - 347

MYELOVAC: A Phase 1 Trial of a Personalized Peptide-Based Neoantigen Vaccination Platform in Combination With Hypomethylating Agent-Based Therapy for Patients With Acute Myeloid Leukemia in First Complete Remission Ineligible for Intensive Chemotherapy and Allogeneic Stem Cell Transplantation

Nikolaos Spyrou

Poster Presenter: Nikolaos Spyrou

ePosters in

Topics Sessions

Acute Lymphoblastic Leukemia (ALL)(71)Acute Myeloid Leukemia (AML)(230)Aggressive B-Cell Lymphoma (ABCL)(114)Cellular Therapy (CT)(128)Chronic Lymphocytic Leukemia (CLL)(110)Chronic Myeloid Leukemia (CML)(55)Hodgkin Lymphoma (HL)(54)Indolent B-Cell Lymphoma (IBCL)(47)Mantle Cell Lymphoma (MCL)(23)Multiple Myeloma (MM)(234)

Previous 1 2 Next

Sponsors